Hvivo

HVO · AIM · Health Care · mcap £41m · 5.8p

hVIVO runs human challenge trials, in which volunteers are deliberately infected with viruses such as flu and RSV in quarantine units to test vaccines and antivirals for pharma and biotech clients. It also offers laboratory services, early-phase clinical units in Germany and bio-storage.

Target	Promise	Said	Status
2025
H2 2025	Complete hMPV characterisation study and commence hMPV human challenge trials from H2 2025	13 Jan 2025	◐ Partly kept
	“should be in a position to commence hMPV HCTs from H225, subject to the successful completion of this study and receipt of the necessary regulatory approvals” Also stated 17 Feb 2025 How it developed 13 Jan 2025 Said “will look to complete the remainder of the characterisation study with a partner in advance of completing future human challenge trials” 17 Feb 2025 Said “should be in a position to commence hMPV HCTs from H225, subject to the successful completion of this study and receipt of the necessary regulatory approvals” 11 Nov 2025 ◐ Partly “The model demonstrated high infection and symptomatic disease attack rates and robust AUC virology by qRT-PCR, and is now ready and available for vaccine...” Status so far hMPV model data presented in November 2025, but no hMPV challenge trial start is reported. “The model demonstrated high infection and symptomatic disease attack rates and robust AUC virology by qRT-PCR, and is now ready and available for vaccine and antiviral human challenge trials.”11 Nov 2025 · Positive data from novel human challenge models
H2 2025	Sign and run ILiAD Phase 3 whooping cough challenge trial, expected to start H2 2025	27 Jan 2025	◐ Partly kept
	“By leveraging hVIVO's extensive experience and expertise in human challenge trials, we plan to generate robust pivotal clinical data to support global marketing authorisation applications for BPZE1.” How it developed 27 Jan 2025 Said “By leveraging hVIVO's extensive experience and expertise in human challenge trials, we plan to generate robust pivotal clinical data to support global...” 22 Apr 2026 ◐ Partly “HVIVO is expected to recognise revenue from H1 2026, with the majority of revenue recognised during 2026 and 2027.” Status so far Contract signed 22 April 2026, later than the H2 2025 start; revenue expected from H1 2026. “HVIVO is expected to recognise revenue from H1 2026, with the majority of revenue recognised during 2026 and 2027.”22 Apr 2026 · HCT contract signed with ILiAD Biotechnologies